SCHEMBL2008360

SCHEMBL2008360

Oc1ccc(-n2ncc3c(O)cc(Cl)cc32)cc1F

nearest known ligand 0.35

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 4/20 0.35
CYP11B2 P19099 4/20 0.34
CYP11B1 P15538 3/20 0.34
GRM1 Q13255 2/20 0.34
CYP17A1 P05093 1/20 0.34
CYP1A2 P05177 1/20 0.34
CCR1 P32246 1/20 0.34
PRKCZ Q05513 1/20 0.34
ESR1 P03372 4/20 0.33
ESR2 Q92731 3/20 0.33
PGR P06401 1/20 0.32
ESRRA P11474 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4437839 0.93 CYP11B2 (0.35) NR3C1CYP11B2CYP11B1GRM1CYP17A1
SCHEMBL4447721 0.89 MAPT (0.35) NR3C1CYP11B2CYP11B1GRM1CYP17A1
SCHEMBL2006894 0.86 NR3C1 (0.38) NR3C1CYP11B2CYP11B1CYP17A1CYP1A2
SCHEMBL2003406 0.83 CYP11B1 (0.38) NR3C1CYP11B2CYP11B1GRM1CYP17A1
SCHEMBL2005767 0.83 ESRRA (0.36) NR3C1CYP11B2CYP11B1GRM1ESR1
SCHEMBL2004925 0.83 ESR1 (0.37) NR3C1CYP11B2CYP11B1ESR1ESR2
SCHEMBL2002221 0.80 PGR (0.40) NR3C1CYP11B2ESR1ESR2PGR
SCHEMBL12572492 0.80 ESR1 (0.33) NR3C1CYP11B2CYP11B1ESR1ESR2
SCHEMBL2006268 0.80 TRPA1 (0.35) NR3C1CYP11B2CYP11B1CCR1ESR1
SCHEMBL2009185 0.80 CYP11B1 (0.39) NR3C1CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US claimed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US claimed
CN-101679288-A Indazoles for treating estrogen receptor beta mediated diseases GLAXO GROUP LTD 2010-03-24 CN claimed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
CN-101679288-A Indazoles for treating estrogen receptor beta mediated diseases GLAXO GROUP LTD 2010-03-24 CN disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB NR3C1 76/4885CYP11B2 14/4885CYP11B1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.